Stockholders Equity (Details) - USD ($) $ / shares in Units, $ in Thousands |
1 Months Ended | 3 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
Mar. 01, 2023 |
Feb. 22, 2023 |
Dec. 31, 2021 |
Oct. 31, 2021 |
Dec. 31, 2020 |
Mar. 31, 2023 |
Dec. 31, 2022 |
Nov. 30, 2017 |
|
| Stockholders Equity (Details) [Line Items] | ||||||||
| Securities purchase agreement, description | the Company entered into a Securities Purchase Agreement to issue and sell an aggregate of 15,997,448 shares of its Common Stock and 14,610,714 pre-funded warrants (the “Pre-Funded Warrants”, and collectively, the “Securities”) at a price of $0.245 per share and $0.244 per Pre-Funded Warrant, through a private investment in public equity financing (“PIPE”). The gross proceeds from this offering are approximately $7,484, before deducting issuance costs. The financing closed in two parts. The first closing, which covers 3,199,491 shares of Common Stock and 2,776,428 Pre-Funded Warrants for gross proceeds of $1,469, occurred on February 27, 2023. Such Pre-Funded Warrants became exercisable on February 27, 2023, at an exercise price of $0.001 per share of Common Stock and have no expiration date. At the first closing the Company raised net proceeds of $1,293, after deducting issuance costs of $176. The second closing for the remaining Securities, which was contingent upon approval of the issuance of the additional Securities under the Securities Purchase Agreement by the Company’s stockholders in accordance with NYSE American rules, occurred on May 4, 2023. See note 10D. | |||||||
| Market sales agreement, description | pursuant to a registration statement on Form S-3 declared effective by the Securities and Exchange Commission on December 11, 2020, the Company entered into an Open Market Sales Agreement (“ATM Agreement”) with Jefferies LLC. (“Jefferies”), which provides that, upon the terms and subject to the conditions and limitations in the ATM Agreement, the Company may elect, from time to time, to offer and sell shares of Common Stock with an aggregate offering price of up to $50,000, with Jefferies acting as sales agent. During the three months ended March 31, 2023, the Company did not sell any shares of Common Stock under the ATM Agreement. During the three months ended March 31, 2022, the Company sold 27,171 shares of Common Stock under the ATM Agreement, at an average price of $1.36 per share, raising aggregate net proceeds of approximately $37, after deducting an aggregate commission of $1. | |||||||
| Contract liability | $ 1,976 | |||||||
| Preferred stock, shares authorized | 1,000,000 | 1,000,000 | ||||||
| Preferred stock, par value | $ 0.0001 | $ 0.0001 | ||||||
| Granted option shares | 1,543,000 | |||||||
| Exercise price | $ 0.001 | |||||||
| Vesting period term | 4 years | |||||||
| Fair value of grant date | $ 487 | |||||||
| Founder [Member] | ||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||
| Shares of issued warrants | 2,974 | |||||||
| Pre-Funded Warrants [Member] | Minimum [Member] | ||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||
| Percentage of ownership | 9.90% | |||||||
| Pre-Funded Warrants [Member] | Maximum [Member] | ||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||
| Percentage of ownership | 9.99% | |||||||
| Stock Options [Member] | ||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||
| Exercise price | $ 0.4 | |||||||
| Maruho Agreement [Member] | ||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||
| Common stock shares issued | 375,000 | |||||||
| Common stock per share | $ 8 | |||||||
| Total gross proceed | $ 3,000 | |||||||
| Grant date fair value | $ 1,024 | |||||||
| CFF Agreement [Member] | ||||||||
| Stockholders Equity (Details) [Line Items] | ||||||||
| Agreement type, description | the Company entered into a Securities Purchase Agreement with the Cystic Fibrosis Foundation (“CF Foundation”), an organization that historically played a role in supporting the development of innovative therapies for patients suffering from cystic fibrosis (CF). Under the terms of the agreement, the Company will receive up to $5,000 in two tranches. In the first tranche, which closed and fully received on December 21, 2021, the CF Foundation invested $3,000 as an initial equity investment based on a share price of $2.57. Upon completion of patient dosing in Part 1 of the Company’s Phase 1b/2a study of BX004, the Company had the right to receive the second tranche of $2,000, also as an equity investment. In the event that the average closing price of the Common Stock for the ten trading days prior to the second tranche completion is less than $2.57, the Company had the right in its sole discretion to waive the second tranche payment and in such event the CF Foundation would not have any right to receive additional shares. Ultimately, the CF Foundation decided to participate in the PIPE and invested an aggregate amount of $2,000 and the Company waived the right to receive the second tranche of $2,000 mentioned above. | |||||||